ARTICLE | Finance
Combo quest
Why NantKwest led Viracta’s B round
April 7, 2017 10:01 PM UTC
By leading Viracta Therapeutics Inc.’s series B round and forging a partnership for its lead HDAC inhibitor last week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal.
Wicklow Capital, Latterell Venture Partners and Forward Ventures joined NantKwest in the tranched $18.4 million series B round...
BCIQ Target Profiles